Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEATcc: Atezolizumab plus platinum–paclitaxel–bevacizumab in metastatic, persistent, or recurrent cervical cancer
jRCT2041190037Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of atezolizumab in Cervical Cancer (CC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Progression-free survival (PFS) and Overall survival (OS). Started Aug 2019; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2041190037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041190037.